FDA investigates cancer risk tied to Novartis gene therapy

The FDA is investigating postmarket reports of malignancies in patients treated with Novartis’ gene therapy Zolgensma for spinal muscular atrophy, including confirmed cases of product-related insertional oncogenesis, according to a Nov. 6 agency safety communication. The agency said it is evaluating whether regulatory action is appropriate. The reports include tumors of the central and peripheral […] The post FDA investigates cancer risk tied to Novartis gene therapy appeared first on Beck...